A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies

BACKGROUND: Inhibition of the epidermal growth factor receptor (EGFR) extends patient survival in multiple tumor types. Skin toxicities are the most common adverse event (AE) elicited by EGFR inhibitors. Here, we provide deeper insights into patients’ and physicians’ acceptance of the risk/benefit t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tischer, Bernd, Bilang, Martina, Kraemer, Matthias, Ronga, Philippe, Lacouture, Mario E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847041/
https://www.ncbi.nlm.nih.gov/pubmed/29116406
http://dx.doi.org/10.1007/s00520-017-3938-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847041/
https://www.ncbi.nlm.nih.gov/pubmed/29116406
http://dx.doi.org/10.1007/s00520-017-3938-7

Ejemplares similares